Semaglutide maka ụdị ọrịa shuga 2

Semaglutide bụ ọgbọ ọhụrụ nke GLP-1 (glucagon-dị ka peptide-1) analogs, yana semaglutide bụ ụdị usoro onunu ogwu na-eme ogologo oge nke emepụtara dabere na ntọala nke liraglutide, nke nwere mmetụta dị mma na ọgwụgwọ ụdị ọrịa shuga 2.Novo Nordisk emechaala 6 Phase IIIa ọmụmụ nke semaglutide injection, ma nyefee akwụkwọ ndebanye aha ọgwụ ọhụrụ maka ọgwụ mgbochi semaglutide kwa izu na US Food and Drug Administration (FDA) na December 5, 2016. A na-edobekwa ngwa ikike ahịa ahịa (MAA). Ụlọ Ọrụ Ọgwụ na Europe (EMA).

E jiri ya tụnyere liraglutide, semaglutide nwere ogologo aliphatic yinye na ụbara hydrophobicity, mana semaglutide na-eji obere yinye PEG gbanwee, na hydrophilicity ya na-abawanye nke ukwuu.Mgbe mgbanwe PEG gasịrị, ọ bụghị naanị na ọ ga-ejikọta ya na albumin, na-ekpuchi saịtị enzymatic hydrolysis nke DPP-4, ma na-ebelata excretion nke akụrụ, gbasaa ọkara ndụ ndụ, ma nweta mmetụta nke mgbasa ozi ogologo oge.